Greenwich LifeSciences Inc is a biopharmaceutical company that is developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variet... Greenwich LifeSciences Inc is a biopharmaceutical company that is developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in most breast cancers at low, intermediate, and high or overexpressor levels. 詳細を表示
STAFFORD, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical...
STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical...
STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company" or "Greenwich"), a clinical-stage biopharmaceutical company focused on its Phase III...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.535 | -3.59543010753 | 14.88 | 15.5 | 14.14 | 39321 | 14.8724963 | CS |
4 | -0.015 | -0.104456824513 | 14.36 | 16.5 | 13.1339 | 40131 | 14.48561218 | CS |
12 | -2.475 | -14.7146254459 | 16.82 | 17.1882 | 12.75 | 33439 | 14.76791626 | CS |
26 | -6.195 | -30.1606621227 | 20.54 | 21.44 | 11.375 | 34223 | 14.98992361 | CS |
52 | 5.655 | 65.0747986191 | 8.69 | 21.44 | 7.58 | 32447 | 13.83563586 | CS |
156 | -26.955 | -65.2663438257 | 41.3 | 41.42 | 6.8241 | 62835 | 13.81633166 | CS |
260 | 9.345 | 186.9 | 5 | 128 | 3.262 | 131455 | 33.48148062 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約